SCM Life Sciences Announces Disease Improvement Effects of Next-Generation Stem Cell Therapy at ISCT 2023

SCM Life Science, a bio company specializing in cell therapy, announced on the 7th that it presented research results on atopic dermatitis animal models using mesenchymal stem cells (MSCs) enhanced by priming technology at the 29th International Society for Cell & Gene Therapy (ISCT), held in Paris, France, from May 31 to June 3 (local time).

SCM Life Science stated, "Through atopic dermatitis animal model research, we confirmed that mesenchymal stem cells enhanced by priming technology (a technique to strengthen stem cell function) significantly increase the therapeutic effect."

Recently, in the field of stem cell research, stem cells whose functions are enhanced by stimulating the immune environment compared to first-generation stem cells have been named second-generation stem cells. Priming research to improve the therapeutic efficacy of mesenchymal stem cells has been actively conducted. SCM Life Science also conducted research on second-generation stem cells and discovered a new combination of immune-stimulating factors that enhance therapeutic effects in atopic dermatitis animal models.

SCM Life Science confirmed that adding IFN-α and Vitamin B6 to the well-known TNF-α and IFN-γ combination significantly increases the expression of immune regulatory factors such as ICOSL, TSG-6, PD-L1, GAL-9, and IL-1RA, and increases Foxp3+IL-10+CD4+ regulatory T cells, which suppress immune cell activation.

Based on this, when primed mesenchymal stem cells were injected into atopic dermatitis animal models, the secretion of IgE was significantly reduced, and the production of IgG2a, which regulates immune balance and alleviates atopic symptoms, was also significantly increased. Additionally, the lesion areas were effectively alleviated, and mast cells, which increase due to inflammation in the atopic dermatitis model, were markedly decreased.

Through this, it was confirmed that primed mesenchymal stem cells have higher therapeutic efficacy in atopic dermatitis animal models compared to conventional mesenchymal stem cells. Thus, SCM Life Science demonstrated the potential of primed mesenchymal stem cells as next-generation stem cell therapeutics.

SCM Life Science currently holds domestic patents recognizing the priming technology of mesenchymal stem cells and is preparing to expand overseas to the United States, Europe, China, Japan, and other regions. In addition to three stem cell therapeutics currently in clinical trials, the company is actively conducting research on next-generation stem cell therapeutics and plans to prepare clinical trials for subsequent pipelines.